Mind Cure Health (CSE: MCUR) has launched a digital therapeutic tool which has been designed to provide near real-time data on patient care while enhancing access to psychedelic research, procedures and protocols in the realm of mental health. Labelled as iSTRYM, the new platform will look to bridge gaps that currently exist between clients, researchers and therapists.
iSTRYM is being described as a centralized management system for a number of functions, including psychedelic therapeutic research, procedural information, and the deployment of care. The platform has utilized technology to record vast uncategorized data, with its app component used by patients to record location, heart rate, weather, mood and other metrics of relevance after therapy sessions to assist in discovering insights across datasets, which will then be used to support better diagnoses from clinicians.
With a focus on psychedelic assisted therapy sessions, the tool will look to collect data that is typically lost between clients, researchers, and therapists. These uncategorized data points, such as listed above, will be collected as a means of enhancing the understanding of patient feedback. This optimization will then be used by the company to create what is referred to as a “converge of commonalities” among patients that utilize the program, enabling deeper insights as a whole to develop what is described as “personalized care at scale.”
“As a life sciences and digital therapeutics company, providing speed to market with novel psychedelic therapies through deeper data analytics is a strength we are developing with iSTRYM. Further, as we build out our database for mental wellness, both therapists and individuals will get mental wellness protocols for wellness optimization and support. iSTRYM exists to become the source that individuals turn to for science-backed, personalized mental health support at scale.”kelsey Ramsden, President & CEO
Mind Cure Health last traded at $0.70 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.